ABSTRACT BACKGROUND AND OBJECTIVE: Hepatitis C virus (HCV) is a serious global health burden. There is no effective vaccine against HCV and new direct acting antivirals (DAAs) are so expensive and virtually unavailable to the public. Therefore, seeking for therapeutic or prophylactic vaccines is exigent and reliever. METHODS: The secondary and tertiary structures of the recombinant Core-NS3 (rC-N) fusion protein of HCV and its B and T-cells epitopes were evaluated with bioinformatics software. Cloning and in vitro expression of rC-N were performed by pET24a(+) and E.coli BL21-DE3 expression host, respectively. The recombinant protein purifi cation was done by affi nity chromatography method and then identifi ed by Western blotting using anti-His monoclonal antibody. RESULTS: The sequences of rC-N protein consist of 1-118 amino acid parts of Core and 1095-1384 amino acids of NS3 were connected by a fl exible linker (AAY) with proteasome cleavable site. The expressed and purifi ed 46.7292 kDa rC-N protein had antigenic value up to threshold and conservancy found in this chimeric protein. Ramchandran Plot analysis represented that most residues were fallen in favourable regions. It also interacted with both type I and II major histocompatibility complex (MHC I, II) molecules. The rC-N had antigenic behaviour to create T cell responses. CONCLUSION: The results indicated that conserved rC-N protein had the ability to induce T-cell-mediated immune responses and it could be utilized as a therapeutic vaccine candidate against HCV (Tab. 3, Fig. 4, Ref. 40). Text in PDF www.elis.sk.
Introduction
Hepatitis C virus (HCV) infection remains a leading cause of liver cirrhosis, hepatocellular carcinoma and lymphomas. The recent estimations showed approximately 185 million people, who are infected with this virus, 73 % of them live in middle-income countries (1, 2) . However, new direct acting antivirals are over 95-99 % effective against chronic HCV genotype 1 and 2, but they are so expensive (about 63-300000 US $, per a period of treatment, with or without cirrhosis) and inaccessible for all patients, especially for those, who live in low and middle income countries. Therefore, seeking for new drugs and therapeutic or anaphylactic vaccines is exigent (3, 4) .
The size of positive sense single stranded RNA genome of HCV is about 9.6 kb and encodes a large poly protein of 3010 to 3033 amino acid residues. The proteins of HCV are arranged along the genome in the following order: N terminal-core-envelope proteins (E1-E2)-p7-nonstructural proteins (NS)-NS2-NS3-NS4A-NS4B-NS5A-NS5B-C terminal (5, 6) .
The core protein with 191 amino acids can be divided into three domains on the basis of hydrophobicity: domain 1 (amino acids 1-117), which contains mainly basic residues with two short hydrophobic regions; domain 2 (amino acids 118-174), which is less basic and more hydrophobic and its C-terminus is at the end of p21; domain 3 (residues 175-191), which is highly hydrophobic and acts as a signal sequence for E1 envelope protein (7) (8) (9) . The sequences of core are the most conserved parts of the hepatitis C genome and have many B cell and T cell epitopes (10) .
Non-structural protein 3 contains a serine protease and an RNA helicase. Protease cleaves the genome-encoded polyprotein and inactivates cellular proteins required for innate immunity. Helicase is required for both genome replication and virus assembly. Special characteristics and relatively preserved structure of NS3 makes it a suitable target for the development of antiviral therapeutics and vaccine research (7, 8, 11) .
Synthetic fusion protein base vaccines are more advanced and applicable in comparison with traditional vaccines. They not only provide opportunities for specifi c purposes, but also can make ability to exclude deleterious sequences from full-length genome. Also, synthetic protein base vaccines are safer than attenuated or inactivated vaccines. Likewise, HCV culture is diffi cult and it can be an essential obstacle to traditional vaccine development (12, 13) .
The CD4+ and CD8+ T cells immune responses are essential for an effective campaign after infection by hepatitis C virus (14, 15) . T cell adoptive transfer therapy or prophylactic vaccine based on Core and NS3 proteins is suitable to induce both CD4+ and CD8+ T cell responses against HCV (16) (17) .
Objectives
The present study aimed to immunoinformatic analysis, modelling and simulation of conserved and immunogenic regions in core and NS3 genes from HCV 1a genotype by using online bioinformatics tools, thereafter, expression and purifi cation of this projected construct to produce recombinant Core-NS3 (rC-N) fusion protein for its potential application as therapeutic vaccine candidate. By the next considerations, the chimeric produced protein will be evaluated solitarily or besides some adjuvants in the future.
Materials and methods

Sequence analysis of recombinant Core, NS3 fusion protein (rC-N)
In order to do in-silico translation of a hepatitis C recombinant fusion protein to obtain amino acid sequences in high levels of CTL epitopes, some parts of core and ns3 gene sequences, corresponding to genotype 1a were derived from the national centre of biotechnology information (hhtp://www.ncbi.nlm.nih.gov). These two peptides were analysed for conserved domains in (NCBIConserved Domains) http://www.ncbi.nlm.nih.gov/Structure/cdd/ cddsrv.cgi?uid=111760.
Physicochemical properties of both fragments were computed using ProtParam online tool (http://web.expasy.org/protparam/) (18) , while a fl exible linker with proteasome cleavable site was predicted by Rankpep (http://bio.dfci.harvard.edu/RANKPEP) and paproc (http://paproc.de) to obtain fi nal rC-N sequence.
Secondary, tertiary structures and disulfi de connectivity of rC-N
Secondary structure prediction and calculating the number of α-helix, β-sheets, turns random coils, and extended strands of rC-N protein were carried out using Self-Optimized Prediction Method with Alignment (SOPMA) (http://npsa-pbil.ibcp.fr/cgibin/npsa_automat.pl?page=/NPSA/npsa_sopma.html) and Jpred (http://www.compbio.dundee.ac.uk/jpred/) tools (19, 20) .
Disulfi de connectivity of the rC-N protein was analysed using DiAminoacid Neural Network Application (DiANNA) tool, which predicts cysteine conditions of proteins that have small number of disulfi de bonds (21). To get informed of cys-cys connection is valuable in perception the secondary and tertiary structure of protein, because it has an important role in fold permanence.
The Iterative Threading ASSEmbly Refi nement (I-TASSER) online server program, which creates three dimensions (3D) models besides their confi dence score (C-Score) was used in order to get tertiary structure prediction. C-score is typically in the range of (-5 to 2), where a C-score of higher value signifi es a model with a high confi dence and vice-versa (22) . Five top patterns were presaged and the best model among them was selected for structural analysis. The pattern was selected by three indicators: C-score, DFIRE2 energy profi le (23) and stereo chemical qualities. Stereo chemical analysis of obtained 3D protein models was performed by PROCHECK, ERRAT, VERIFY 3D programs for structural analysis, which was authenticated by Structure Analysis and VErifi cation Server (SAVES) (http://nihserver.mbi.ucla. edu/SAVES) and ramachandram plot assessment (RAM-PAGE) (mordred.bioc.cam.ac.uk/~rapper/rampage.php) (24) (25) (26) (27) .
Prediction of T-cell epitopes from rC-N
T-cell epitope regions of rC-N were predicted using the web servers SYFPEITHI (http://www.syfpeithi.de/), ProPred-I (http:// www.imtech.res.in/raghava/propred1/) and IEDB (http://tools. iedb.org). The cut-off score was adjusted to≥18 for SYFPEITH (28, 29) . The outcomes revealed a classifi ed list of nine amino acid sub-strands of the proffered antigen sequence for affi nity computations (30) .
Prediction of rC-N antigenicity
The antigenicity scores of all the predicted epitopes were examined by VaxiJen v2.0 online antigen prediction tool (http://www. ddg-pharmfac.net/vaxijen/). Epitopes having antigenic score > 0.5 were selected as antigenic. VaxiJen v2.0 allows antigen assortment based on the physicochemical qualities of proteins without the use of sequence alignment (31) .
Cloning and expression of rC-N protein
The corresponding rC-N fragment (Core 1-118 aa, AAY linker and NS3, aa 1095-1387), was synthesised using Biomatik company (Canada) and was inserted into BamH I and EcoR I restriction sites of the pET24.a (+) vector, a T7 promoter based plasmid (Invitrogen, USA) and the recombinant construct was transformed into E. coli BL21-DE3 expression system (Invitrogen, USA). Then, induction was carried out with 1 mM isopropyl B-D-thiogalactopyranoside (IPTG) (SinaClon bioscience Co, Iran) at 37 °C for 4 hours. Finally, lysate of bacteria expressing rC-N protein was analysed using Poly Acrylamide Gel Electrophoresis on 12% sodium dodecyl sulfate (SDS-PAGE).
Protein purifi cation under native condition
The recombinant rC-N fusion was purifi ed in native condition using Affi nity chromatography method on a nickel-nitrilotriacetic acid (Ni-NTA)-agarose column (Qiagen, Germany) according to the manufacturer procedure. Briefl y, the lysate of bacteria expressing rC-N protein was solubilised by lysis buffer containing 2.5 mM imidazole and after 1hour incubation on ice and sonication, the lysate was applied to the Ni-NTA column and following three times washing steps by washing buffer (50 mM imidazole), the purifi ed rC-N was eluted by elution buffer (250 mM imidazole). To remove a high concentration of imidazole, evaluation sample was subsequently exchanged to PBS by overnight dialysis (cut off: 10 KDa, Sigma, USA) at 4°C. and fi nally protein concentration was measured by Bradford method according to standard protocols.
SDS-PAGE and Western blotting analysis
The purifi ed rC-N protein was analysed by SDS-PAGE and western blotting. The bacterial pellets were suspended in a loading buffer, heated for 5 minutes at 95 °C, and 25 μL of sample was subjected to 15 % SDS-PAGE gel. Western blotting was used in order to verify the purifi ed rC-N protein. In this stage, after purifi cation, the sample was separated by the SDS-PAGE and transferred on nitrocellulose membrane. The membrane was incubated with the conjugated His-tag antibody (Roche, Germany) for 1 hour at room temperature and developed by 3,3'-Diaminobenzidine (DAB) solution (Bio-Rad USA).
Results
Position of rC-N in HCV full genome and its arrangement
The schematic arrangement of the rC-N protein (Domain 1 from Core, truncated middle region of NS3 that consists of some conserved parts of protease and helicase of NS3 and AAY linker between them) is indicated in Figure 1 .
Physiochemical, Sequences and structural analysis of rC-N protein
Physiochemical characterization of the rC-N consisted of 437 amino acids with an estimated molecular weight of 46.7292 kDa and theoretical isoelectric point of 10.05, with the calculated grand average hydropathicity of -0.392, which indicates rC-N is soluble and hydrophilic in nature. The total number of positively charged residues (Arg+ Lys) in the polypeptide was 51, and 27 of negatively charged residues (Asp+ Glu). The protein also contains 4 disulfi de bridges (Tab. 1).
Secondary structure of the rC-N protein showed that random coil makes the 55.61 % of the protein while sheets, helices and turn contribute 24.71 %, 11.67 % and 8.01 of the structure, respectively ( Fig. 2A) .
Tertiary structure of the rC-N protein was predicted using the I-TASSER online server and the best predicted structure with the maximum confi dence score (C-Score:-1.57) was selected from a set of top models ( Figs 2B and 2C) .
Prediction of T-cell epitopes
T-cell epitope regions of rC-N were predicted using the web servers SYFPEITHI (http://www.syfpeithi.de/), ProPred-I (http:// www.imtech.res.in/raghava/propred1/) and IEDB (http://tools. iedb.org). The cut-off score was adjusted to ≥ 18 for SYFPEITH (22, 23) . The outcomes revealed a classifi ed list of nine amino acid sub-strands of the proffered antigen sequence for affi nity computations (24) .
Epitopes belonging to T cell epitopes were revealed on MHC I and MHCII. We used ProPred-I, IEDB and SYFPEITHI servers for the prediction of T-cell epitopes, with 3 (H-2Kd, H-2Dd and H-2Ld) alleles for MHC class I, and 2 (H2-IAd and H2-IEd) alleles for MHC class II. The epitopes with top score were predicted for MHC class I and II (Tabs 2 and 3). For MHC class I, 5 epitopes (FYGKAIPPL, HPNIEEVAL, RGPRLGVRA, PRGRRQPIP and LLPRRGPRL) showed antigenicity score greater than antigenicity threshold (0.5).
Evaluation of the recombinant protein
The pET24a+ expression vector harbouring rC-N gene was confi rmed using a restriction analysis (Fig. 3) . Expression of fusion rC-N gene in E.coli BL21-DE3 resulted to a C-terminally 6x His-tagged protein that provided a simplifi ed purifi cation process. Evaluation of rC-N protein using SDS-PAGE method indicated that the produced protein after IPTG induction was corresponding to 46.7292 kDa fusion protein (Core 1-118 aa, AAY linker and NS3, aa 1095-1387). The homogenous protein band under native condition was purifi ed and the protein size was determined about 47 KDa in accordance to the calculated theoretical value by compute MW/pI tool (www.us.expasy.org) (Fig. 4) .
Discussion
Current vaccines against HCV couldn't produce robust and broadly cross-reactive CD4 + , CD8 + T-cells and neutralizing antibody (NAb) responses and couldn't prevent the virus completely. Therefore, as a realistic goal, a vaccine should prevent the progression of HCV infection to chronic and persistent infection by immunotherapy (32) . Up to now, there isn't any licensed therapeutic vaccine against HCV. With the improvement of bioinformatics, computational analysis and prediction of genomic and post-genomic structures of antigens became an applied approach in the fi rst step 
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for vaccine design (33) . Investigations showed the numerous in silico studies had examined the effects of various vaccines on pathogenic viruses, and indicated that the vaccines targets are mostly proteins (34) . Therefore, in order to induce potent and fi rm immunological responses, specially cellular type, core and NS3 as two highly conserved immunogenic antigens of HCV with multi-specifi c CD8 + and CD4 + T-cell responses were selected. These specifi cations make them attractive for peptide-based therapeutic vaccine design (35) . But, full length of NS3 by protease and helicase enzymatic activities may disturb the APCs activities and reduce suffi cient immune responses (36) . Moreover, C-terminal domain of core is essential for processing of HCV, and previous studies showed a suppression of immune response by full length of core in murine model (37, 38) , and also, both terminals of core HCV have autoimmune sequences that are deleterious for vaccine activity (39) . Then we used the middle region of NS3, containing some parts of helicase and protease of NS3 and fi rst domain of core without C terminus of core in order to design and construct a recombinant fusion protein as an effi cient candidate for HCV therapeutic vaccine. Herein, in silico analysis was applied in computational biotechnology for rational verifi cation and designing of rC-N protein for HCV vaccine development. Accordingly, a new fused construct of hepatitis C peptides including core (1-118) and NS3 (1095-1384) was designed, constructed, expressed and purifi ed as an antigen. A protease-sensitive linker (AAY) was placed between them, in order to optimize the site of fi ssion to facilitate the processing of this bipartite fusion protein and decrease altered bioactivity of the protein moieties by the juxtaposition of the epitopes (40). This protein has four disulfi de bridges (Table 1) , which render extracellular stability in its structure. Ramachandran plot analysis through RAMPAGE of the predicted model resulted in the favoured region and showed that most of the residues are in the allowed regions of the plot, then proving validity of the model. The I-TASSER online server was used to provide the most accurate structure. The C-Score is an evaluation of the statue of the predicted models by I-TASSER and is calculated based on the importance of threading template alignments and the proximity parameters of the structure assembly reproductions (21). The value of C-score was in the acceptable confi dence (-1.57).
The MHC class I presented by target cells along with MHC class II epitopes presented by APCs with antigenic value up to threshold and conservancy predicted in this chimeric protein.
Pursuant to aforementioned predictions and results, rC-N has antigenic behaviour to create CD4+, CD8+ T cell responses. The present fusion protein is a scaffold for therapeutic vaccine. This study showed the capability of the rC-N in virtual environment, but it will be challenged in solitude or with different adjuvants in vivo to improve immune responses in BALB/c mice, with regard to further evaluation to produce fi rstly an effective cellular, and or humoral immunity. 
